This is one product acquisition that fits really well with Shire. I think competition in prophylaxis space is over rated, even though competition in acute space is fierce which is exactly why Shire bought VPHM. Sure, it is expensive. But BMRN is going to be much more expensive if being acquired. BMRN is mini Genzyme, an acquisition would more likely be full standing operation via SNY-Genzyme model IMO, but with much higher premium over what Genzyme got a few years back due to circumstances.
Market Data 
Markets 
AI
